Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

Biagio Ricciuti, Carlo Genova, Maria Bassanelli, Andrea De Giglio, Marta Brambilla, Giulio Metro, Sara Baglivo, Maria Giovanna Dal Bello, Anna Ceribelli, Francesco Grossi, Rita Chiari

Research output: Contribution to journalArticle

Abstract

The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.

Original languageEnglish
JournalClinical Lung Cancer
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Safety
Immunotherapy
Survival
nivolumab
tributyl phosphate
Therapeutics

Keywords

  • Nivolumab
  • NSCLC
  • Pseudoprogression
  • RECIST
  • Treatment beyond progression

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression. / Ricciuti, Biagio; Genova, Carlo; Bassanelli, Maria; De Giglio, Andrea; Brambilla, Marta; Metro, Giulio; Baglivo, Sara; Dal Bello, Maria Giovanna; Ceribelli, Anna; Grossi, Francesco; Chiari, Rita.

In: Clinical Lung Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Ricciuti, Biagio ; Genova, Carlo ; Bassanelli, Maria ; De Giglio, Andrea ; Brambilla, Marta ; Metro, Giulio ; Baglivo, Sara ; Dal Bello, Maria Giovanna ; Ceribelli, Anna ; Grossi, Francesco ; Chiari, Rita. / Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression. In: Clinical Lung Cancer. 2019.
@article{216276a5922748bb81861dc1033b370f,
title = "Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression",
abstract = "The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.",
keywords = "Nivolumab, NSCLC, Pseudoprogression, RECIST, Treatment beyond progression",
author = "Biagio Ricciuti and Carlo Genova and Maria Bassanelli and {De Giglio}, Andrea and Marta Brambilla and Giulio Metro and Sara Baglivo and {Dal Bello}, {Maria Giovanna} and Anna Ceribelli and Francesco Grossi and Rita Chiari",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cllc.2019.02.001",
language = "English",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Safety and Efficacy of Nivolumab in Patients With Advanced Non–small-cell Lung Cancer Treated Beyond Progression

AU - Ricciuti, Biagio

AU - Genova, Carlo

AU - Bassanelli, Maria

AU - De Giglio, Andrea

AU - Brambilla, Marta

AU - Metro, Giulio

AU - Baglivo, Sara

AU - Dal Bello, Maria Giovanna

AU - Ceribelli, Anna

AU - Grossi, Francesco

AU - Chiari, Rita

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.

AB - The possibility of delayed immune-related responses implies that patients who experience progressive disease may benefit from treatment with immunotherapy beyond progression (TBP). Here we demonstrated that a substantial proportion of patients with non–small-cell lung cancer treated with nivolumab, who were clinically stable and judged to be eligible for TBP derive a significant survival benefit from TBP. TBP is feasible and safe, and reduction or stabilization of target lesions may occur when patients with non–small-cell lung cancer continue nivolumab after initial progression. Discontinuation of nivolumab based only on radiologic progression might be premature.

KW - Nivolumab

KW - NSCLC

KW - Pseudoprogression

KW - RECIST

KW - Treatment beyond progression

UR - http://www.scopus.com/inward/record.url?scp=85063165715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063165715&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.02.001

DO - 10.1016/j.cllc.2019.02.001

M3 - Article

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -